Breast cancer is now the most common cancer worldwide, and human Epidermal Growth Factor Receptor-2 (HER-2) positive breast cancer is more malignant, prone to recurrence and metastasis, and has a poor prognosis.However, the advent of trastuzumab monoclonal antibody, a targeted drug, has since improved the prognosis of patients, and a series of anti-HER-2 targeted drugs have since emerged, including pertuzumab monoclonal antibody, inetol monoclonal antibody, tyrosine kinase inhibitors (Neratinib, Lapatinib, Pyrrolitinib, Tucatinib), antibody drug conjugates (T-DM1, DS-8201, SYD985), etc.This paper reviews the progress of targeted therapy for HER-2-positive breast cancer by different mechanisms of action as follows.

Zilin Wu, Peng Xu, Likun Wang. Progress of targeted therapy for HER-2 positive breast cancer. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 6: 77-83. https://doi.org/10.25236/AJMHS.2023.040612.

[1] Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020 [J]. Cancer Commun (Lond), 2021, 41(11): 1183-94. 

[2] Weng Yujie, Liang Wei, Ji Yucheng et al. Key Genes and Prognostic Analysis in HER2+ Breast Cancer. [J]. Technol Cancer Res Treat, 2021, 20: 1533033820983298. 

[3] Sun Tonghui. Effect of trastuzumab on survival of patients with stage T1 HER-2-positive early breast cancer [D]; Xinjiang Medical University, 2021. 

[4] Hu Linyan, Shan Huiguo, Zhou Xuefeng. Clinical study of trastuzumab for the treatment of human epidermal growth factor receptor 2-positive patients after radical breast cancer surgery [J]. Modern Medicine and Health Research Electronic Journal, 2021, 5(19): 35-7. 

[5] Dang Shaohua, Xu Min, Hu Jinyue, et al. Prognosis and influencing factors of neoadjuvant chemotherapy combined with trastuzumab in breast cancer patients with positive HER-2 [J]. Journal of Modern Oncology, 2021, 29(15): 2620-4. 

[6] Xiong BJ, Lv DP, Cao BQ, et al. Trastuzumab treatment in 229 cases with human epidermal growth factor receptor 2 positive stage Ⅳ breast cancer [J]. Oncology Progress, 2021, 19(01): 23-7+45. 

[7] Zi Chunze, Yang Xin, Xie Zenze, et al. Progress of Trastuzumab combined with Pertuzumab in the treatment of HER2-positive breast cancer [J]. Chinese Journal Of Geriatric Care, 2021, 19(03): 110-2. 

[8] Shao Z, Tseng L M, Huang C S, et al. Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study [J]. Jpn J Clin Oncol, 2021, 51(3): 345-53. 

[9] Piccart M, Procter M, Fumagalli D, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2021, 39(13): 1448-57. 

[10] Huang S. F. Efficacy of patuximab combined with trastuzumab in the neoadjuvant treatment of HER-2-positive breast cancer and analysis of influencing factors [D]; Lanzhou University, 2021. 

[11] Swain S M, Miles D, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [J]. The Lancet Oncology, 2020, 21(4): 519-30. 

[12] Suleman K, Mushtaq A H, Haque E, et al. Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs [J]. Breast Care (Basel), 2021, 16(1): 59-65. 

[13] Bian Li, Xu Binghe, Di Lijun, et al. Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer:the HOPES Study [J]. National Medical Journal of China, 2020, 100(30): 2351-7. 

[14] China Anti-Cancer Association Breast Cancer Committee. Guidelines and norms for the diagnosis and treatment of breast cancer of the Chinese Anti-Cancer Association (2021 edition) [J]. China Oncology, 2021, 31(10): 954-1040. 

[15] Tan A R, Im S-A, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study [J]. The Lancet Oncology, 2021, 22(1): 85-97. 

[16] Dumond B, Patel V, Gross A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach [J]. J Oncol Pharm Pract, 2021, 27(5): 1214-21. 

[17] Chen Yimeng, Xu Binghe. Progress of tyrosine kinase inhibitors in HER-2 positive breast cancer [J]. Chinese Clinical Oncology, 2021, 26(03): 265-71. 

[18] Zeng Jiajia, Dong J, Deng Zhihong, et al. Clinical effect of lapatinib in the treatment of metastatic breast cancer with positive HER-2 [J]. Clinical Research and Practice, 2021, 6(25): 67-9. 

[19] Wang Su-E, Dong Lin, Hu Xiaona. Efficacy and Safety of Lapatinib and Capecitabine for Patients with HER-2 Positive Breast Cancer [J]. The Practical Journal of Cancer, 2021, 36(02): 293-6+300. 

[20] Han Mengmeng, Feng Xueyuan, Ma Ning. Research progress of targeted therapy in human epidermal growth factor receptor-2 positive breast cancer [J]. Chinese Archives of General Surgery (Electronic Edition), 2021, 15(06): 453-8. 

[21] Chan A, Moy B, Mansi J, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial [J]. Clinical breast cancer, 2021, 21(1): 80-91. e7. 

[22] Dai M S, Feng Y H, Chen S W, et al. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens [J]. Breast Cancer Res Treat, 2021, 189(3): 665-76. 

[23] Chila G, Guarini V, Galizia D, et al. The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer [J]. Drug Des Devel Ther, 2021, 15(2711-20. 

[24] Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial [J]. The Lancet Oncology, 2021, 22(3): 351-60. 

[25] Yang H, Wang W. Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study [J]. American journal of translational research, 2021, 13(9): 10863-70. 

[26] Le Du F, Dieras V, Curigliano G. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer [J]. Eur J Cancer, 2021, 154(175-89. 

[27] Mueller V, Wardley A, Paplomata E, et al. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial) [J]. Eur J Cancer, 2021, 153(223-33. 

[28] Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases [J]. Crit Rev Oncol Hematol, 2021, 161(103329. 

[29] Lv X. S., Luo B. The research progress on the resistance mechanism of anti-HER-2 therapy [J]. Journal of Modern Oncology, 2022, 30(03): 529-34. 

[30] Ramagopalan S, Pisoni R, Zenin A, et al. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer [J]. Journal of comparative effectiveness research, 2021, 10(7): 595-602. 

[31] Yan BX, Huang SF, Xia YX, et al. The Meta-analysis of the efficacy and safety of trastuzumab-emtansine (T-DM1)in the treatment of HER-2 positive advanced breast cancer [J]. Journal of Modern Oncology, 2021, 29(14): 2447-53. 

[32] Huang C S, Yang Y, Kwong A, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study [J]. Breast Cancer Res Treat, 2021, 187(3): 759-68. 

[33] Denduluri N, Somerfield M, Chavez-Macgregor M, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2021, 39(6): 685-93. 

[34] Yin BX, Huang SF, Xia YX, et al. A Meta-analysis of the efficacy and safety of T-DM1 contained regime for neoadjuvant treatment in HER-2 positive breast cancer [J]. Journal of Lanzhou University (Medical Edition), 2021, 47(03): 1-7. 

[35] Zhu YH, Li T, Hu XC. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(08): 754-61. 

[36] Nader-Marta G, Martins-Branco D, De Azambuja E. How we treat patients with metastatic HER2-positive breast cancer [J]. ESMO open, 2022, 7(1): 100343. 

[37] X. X. Wang, J. X. Wang. Advances in antibody-drug conjugates in the treatment of breast cancer [J]. Journal of Modern Oncology, 2021, 29(12): 2187-2191. 

[38] Manich C S, O Shaughnessy J, Aftimos P G, et al. LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physiciaŽ s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer [J]. Annals of Oncology, 2021, 32(55):1288.